Clinical Trial: Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML

U.S., May 27 -- ClinicalTrials.gov registry received information related to the study (NCT07605949) titled 'Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML' on May 18.

Brief Summary: This study is testing a new treatment combination called RAVEN, which includes revumenib, azacitidine, and venetoclax, in patients who are newly diagnosed with a specific type of acute myeloid leukemia (AML) called KMT2A- translocated AML.

People with this type of AML often have poor outcomes, so new treatments are needed that may work better and cause fewer side effects.

The study has two parts:

1. Induction Phase: Patients will receive treatment for up to 3 cycles. Each cycle lasts 28 days. The goal is to help the leukemia g...